We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here


Potential of immunotherapy in MCL landscape

Friday, August 18, 2017

Peter Martin, M.D., assistant professor of medicine at Weill Cornell Medicine/NewYork-Presbyterian Hospital, spoke to OncLive about the potential of modern immunotherapies in the landscape of mantle cell lymphoma (MCL).

Immunotherapy has been in the field of MCL for a long time, Martin explains, with rituximab (Rituxan). However, when discussing the modern era of immunotherapy with immune checkpoint inhibitors, there has not been enough investigation to determine its potential.

Small clinical trials have suggested that checkpoint inhibitors have limited efficacy, but the truth may be that they are not being used appropriately in order to be used to its highest potential.